Background Image
Previous Page  146 / 156 Next Page
Show Menu
Previous Page 146 / 156 Next Page
Page Background





Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA. Breakthrough pain in community-

dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characte-

ristics. J Opioid Manag 2010; 6(2): 97-108.


Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-

blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of

breakthrough cancer pain. Pain 2010; 151(3): 617-624.


Portenoy RK, Messina J, Xie F, Peppin J. Fentanyl buccal tablet (FBT) for relief of break-

through pain in opioid-treated patients with chronic low back pain: a randomized,

placebo-controlled study. Curr Med Res Opin 2007; 23(1): 223-233.


Portenoy RK, Raffaeli W, Torres LM, Sitte T, Deka AC, Herrera IG, Wallace MS; Fentanyl

Nasal Spray Study 045 Investigators Group. Long-term safety, tolerability, and consistency

of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant

patients. J Opioid Manag 2010; 6(5): 319-328.


Portenoy RK, Sibirceva U, Smout R, Horn S, Connor S, Blum RH, Spence C, Fine PG. Opioid

use and survival at the end of life: a survey of a hospice population. J Pain Symptom

Manage 2006; 32(6): 532-540.


Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of

fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J

Pain 2006; 22(9): 805-811.


Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von

Gunten CF, Israel RJ. Subcutaneous methylnaltrexone for the treatment of opioid-induced

constipation in patients with advanced illness: a double-blind, randomized, parallel

group, dose-ranging study. J Pain Symptom Manage 2008; 35(5): 458-468.


Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, Wolfram G. Efficacy and

safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 pati-

ents with severe cancer pain. J Pain Symptom Manage 2008; 36(2): 117-125.


Przeklasa-Muszynska A, Dobrogowski J. Transdermal buprenorphine for the treatment

of moderate to severe chronic pain: results from a large multicenter, non-interventional

post-marketing study in Poland. Curr Med Res Opin 2011; 27(6): 1109-1117.


Rakhman E, Shmain D, White I, Ekstein MP, Kollender Y, Chazan S, Dadia S, Bickels J, Amar

E, Weinbroum AA. Repeated and escalating preoperative subanesthetic doses of ketami-

ne for postoperative pain control in patients undergoing tumor resection: a randomized,

placebo-controlled, double-blind trial. Clin Ther 2011; 33(7): 863-873.


Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for

breakthrough pain in patients with cancer: a randomized, double-blind, placebo-cont-

rolled study. Ann Oncol 2010; 21(6): 1308-1314.


Rauck RL, Tark M, Reyes E, Hayes TG, Bartkowiak AJ, Hassman D, Nalamachu S, Derrick

R, Howell J. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating

tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009; 25(12):